PT-日记文章Au -Humbert，M.Au -Barst，R.J。Au -Robbins，I.M.Au -Channick，R.N。Au -Galiè，N。au -au -boonstra，A.Au -Rubin，L.J。au -horn，E.M.Au -Manes，A.Au -au -au -au -au -au -au -au -simonneau，G。ti-波森坦与卵巢苯酚与肺动脉高压中的雌烷醇组合：呼吸2 AID：-10.1183/09031936.04.00028404 DP -2004 SEP 01 TA-欧洲呼吸杂志PG -353---359 VI -24 IP -3 4099 -http：//www.qdcxjkg.com/content.com/content/content/24/3/3/3/3/3/3/3/3/3/3/3/3/3/3/3/3/33/3/3/33/3/33/3/33/3/3/100-http：//www.qdcxjkg.com/content/24/3/353.full so -eur Respir j2004 sep 01;24 AB-研究了对肺动脉高压（PAH）的治疗，将波森坦（一种口服双重内皮素受体拮抗剂和雌酮酚）结合的疗效和安全性。在这项双盲，安慰剂对照的前瞻性研究中，有33例PAH患者开始治疗（2 ng·kg-kg-1min-1的起始剂量，在第16周，最高14±2 ng·kg-1min-1），被随机化在2：1的比例与波森坦（62.5 mg B.I.D）的比例为16周，持续4周，然后125 mg B.I.D）或安慰剂。两组在第16周的血液动力学，运动能力和功能类别都改善了。在联合治疗组中，所有测得的血液动力学参数的趋势都有更大（尽管不显着）的趋势。波森坦/雌烯醇组有四次戒断（由于心肺衰竭而导致的两次死亡，一次临床恶化和1次不良事件），安慰剂/eproprostenol组（不良事件）中有1次戒断。 This study showed a trend but no statistical significance towards haemodynamics or clinical improvement due to the combination of bosentan and epoprostenol therapy in patients with pulmonary arterial hypertension. Several cases of early and late major complications were reported. Additional information is needed to evaluate the risk/benefit ratio of combined bosentan-epoprostenol therapy in pulmonary arterial hypertension. This study was supported by Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.